TG Therapeutics, Inc.
TGTX
$33.59
$0.190.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.54% | 40.80% | 39.53% | 1,341.63% | 3,275.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.54% | 40.80% | 39.53% | 1,341.63% | 3,275.73% |
| Cost of Revenue | 159.60% | 172.34% | 392.68% | 805.45% | 2,014.69% |
| Gross Profit | 24.83% | 32.34% | 27.44% | 1,411.50% | 3,420.93% |
| SG&A Expenses | 31.60% | 25.75% | 28.44% | 43.70% | 66.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.52% | 34.76% | 27.11% | 27.05% | 40.49% |
| Operating Income | 23.71% | 103.21% | 97.33% | 160.37% | 129.67% |
| Income Before Tax | 0.30% | 95.94% | 46.40% | 154.53% | 124.69% |
| Income Tax Expenses | 518.14% | 466.92% | -- | -- | -- |
| Earnings from Continuing Operations | -4.97% | 84.52% | 44.55% | 154.47% | 124.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.97% | 84.52% | 44.55% | 154.47% | 124.44% |
| EBIT | 23.71% | 103.21% | 97.33% | 160.37% | 129.67% |
| EBITDA | 23.37% | 101.48% | 97.82% | 160.56% | 129.83% |
| EPS Basic | -6.17% | 100.50% | 51.41% | 152.95% | 123.31% |
| Normalized Basic EPS | -0.94% | 112.69% | 53.08% | 153.00% | 123.54% |
| EPS Diluted | 10.97% | 1,308.25% | 58.75% | 146.91% | 117.55% |
| Normalized Diluted EPS | 16.48% | 823.08% | 61.98% | 147.42% | 118.14% |
| Average Basic Shares Outstanding | 1.41% | 2.38% | 3.09% | 4.09% | 4.78% |
| Average Diluted Shares Outstanding | 9.63% | 7.89% | 6.03% | 9.08% | 7.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |